Seoul Pharma Co. Ltd (018680) - Total Assets
Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) holds total assets worth ₩74.00 Billion KRW (≈ $50.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 018680 net asset value for net asset value and shareholders' equity analysis.
Seoul Pharma Co. Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Seoul Pharma Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Seoul Pharma Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Seoul Pharma Co. Ltd's total assets of ₩74.00 Billion consist of 45.0% current assets and 55.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩7.54 Billion | 10.5% |
| Accounts Receivable | ₩9.13 Billion | 12.7% |
| Inventory | ₩12.10 Billion | 16.9% |
| Property, Plant & Equipment | ₩33.86 Billion | 47.3% |
| Intangible Assets | ₩809.45 Million | 1.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Seoul Pharma Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Seoul Pharma Co. Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seoul Pharma Co. Ltd's current assets represent 45.0% of total assets in 2024, an increase from 30.9% in 2012.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, up from 5.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is property, plant & equipment at 47.3% of total assets.
Seoul Pharma Co. Ltd Competitors by Total Assets
Key competitors of Seoul Pharma Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF21.61 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Seoul Pharma Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.17 | 2.62 | 1.41 |
| Quick Ratio | 1.40 | 1.46 | 1.00 |
| Cash Ratio | 0.00 | 0.70 | 0.00 |
| Working Capital | ₩19.30 Billion | ₩17.02 Billion | ₩7.49 Billion |
Seoul Pharma Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Seoul Pharma Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 13.1% |
| Total Assets | ₩71.62 Billion |
| Market Capitalization | $22.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Seoul Pharma Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Seoul Pharma Co. Ltd's assets grew by 13.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Seoul Pharma Co. Ltd (2012–2024)
The table below shows the annual total assets of Seoul Pharma Co. Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩71.62 Billion ≈ $48.54 Million |
+13.13% |
| 2023-12-31 | ₩63.31 Billion ≈ $42.90 Million |
+1.41% |
| 2022-12-31 | ₩62.43 Billion ≈ $42.31 Million |
+0.29% |
| 2021-12-31 | ₩62.25 Billion ≈ $42.19 Million |
-4.36% |
| 2020-12-31 | ₩65.09 Billion ≈ $44.11 Million |
-8.19% |
| 2019-12-31 | ₩70.89 Billion ≈ $48.04 Million |
-21.73% |
| 2018-12-31 | ₩90.57 Billion ≈ $61.38 Million |
+4.18% |
| 2017-12-31 | ₩86.93 Billion ≈ $58.91 Million |
-6.06% |
| 2016-12-31 | ₩92.54 Billion ≈ $62.71 Million |
+11.93% |
| 2015-12-31 | ₩82.68 Billion ≈ $56.03 Million |
+4.68% |
| 2014-12-31 | ₩78.98 Billion ≈ $53.52 Million |
+10.58% |
| 2013-12-31 | ₩71.42 Billion ≈ $48.40 Million |
+17.71% |
| 2012-12-31 | ₩60.68 Billion ≈ $41.12 Million |
-- |
About Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more